Expression Analyses of Epidermal Growth Factor Receptor and HER-2/neu: No Advantage of Prediction of Recurrence or Survival in Breast Cancer Patients

Oncology (Switzerland)

Volumn 53, Issue 6, 1996, Pages 441-447

  Beckmann, Matthias W ^a   Niederacher, Dieter ^a   Massenkeil, Gero ^a   Tutschek, Boris ^a   Beckmann, Andreas ^a   Schenko, Gerhard ^a   Schnürch, Hans Georg ^a   Bender, Hans Georg ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Breast cancer; Epidermal growth factor receptor protein; HER 2 neu; Immunohistochemistry; Steroid hormone receptors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0029859395     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227618     Document Type: Article

References (55)

1. Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, Lancet 1992;339:1-15.
2. Russo J, Calaf G, Sohi N, Tahin Q, Zhang PL, Alvarado ME, Estrada S, Russo IH: Critical steps in breast carcinogenesis, Ann NY Acad Sci 1993;698:1-20.
3. Horak ER, Harris AL, Stuart N, Bickncll R: Angiogenesis in breast cancer: Regulation, prognostic aspects, and implications for novel treatment strategies, Ann NY Acad Sci 1993: 698:71-84.
4. Downward J, Yarden Y, Mayes E: Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences, Nature 1984;307:521-527.
5. Carpenter G: Receptors for epidermal growth factor and other polypeptide mitogens, Annu Rev Biochcm 1987:56:881-914.
6. Sainsburv JRC, Malcolm AJ, Appleton DR, Farndon JR, Harris AL: Presence of epidermal growth factor receptors as an indicator for poor prognosis in patients with breast cancer, J Clin Pathol 1985;38:1225-1231.
7. Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal growth factor receptor status as a predictor of relapse and death from breast cancer, Lancet 1987;i: 1398- 1402.
8. Costa SD, Kaufmann M, Fabro D, Tokus T, Fcichter G, Bastcrt G: Epidermal growth factor receptors and flow cytometry in primary breast cancer: Relationship to hormone receptors and lymph node status, Geburtshilfe Frauenheilkd 1989;9:375-378.
9. Toi M, Hamada Y, Nakamura T, Mukaida H, Suchiro S, Wada T, Toge T, Niimoto M, Hatto-ri T: Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: Relationship to estrogen receptor and lymphatic invasion, Int J Cancer 1989:43:220-225.
10. Grimaux M, Mady E, Rentvikos Y, Laine-Bidron C, Magdclenat H: A simplified imrnu-nocnzymetric assay of the epidermal growth factor receptor in breast tumors: Evaluation in 282 cases, Int J Cancer 1990;45:255-262.
11. Lewis S, Locker A, Todd JH, Bell JA, Nicholson R, Elston CW, Blarney RW, Ellis 10: Expression of epidermal growth factor receptor in breast carcinoma, J Clin Pathol 1990:43:385-389.
12. Scharl A, Gohring UJ, Vicrbuchen M, Kiistcrs B, Wiirz H: Epidermal growth factor receptor (EGF-R) - A marker for morphological and functional anaplasia in human breast carcinoma, Geburtshilfe Frauenheilkd 1990:50:877-882.
13. Nicholson S, Richard J, Sainsbury C: Epidermal growth factor receptor (EGFR): result of a 6 year follow-up study in operable breast cancer with emphasis on node negative subgroup, Br J Cancer 1991:63:146-150.
14. Koenders PG, Farverly D, Beex LVAM, Brug-gink EDM, Kicnhuis CBM, Benraad TJ: Epidermal growth factor receptors in human breast cancer: A plea for standardization of assay methodology, EurJ Cancer 1992:28:693- 697.
15. Nicholson RI, McClelland RA, Gee JMW, Manning DL, Cannon P, Robertson JFR, Ellis IO, Blarney RW: Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy, Breast Cancer Res Treat 1994:29:117-125.
16. Schcchter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, Ullrich A, Coussens L: The neu gene: An crb-homologous gene distinct and unlinked to the gene encoding the EGF-receptor, Nature 1985: 229:976-978.
17. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlcssinger J, Francke U, Levinson A, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal localization withneuoncogene, Science 1985;230:1 132-1139.
18. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor, Nature 1986;319:230-234.
19. Holmes WE, Sliwkowski MX, Akita RW, Hen-zel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab LL, Lewis GD, Shepard HM, Kuan W-J, Goeddcl DV, Vandlen RL: Identification of heregulin, a specific activator of pl85crbB2, Science 1992;256:1205-1210.
20. Pietras RJ, Arboleda L, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells, Oncogene 1995:10:2435-2446.
21. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/wn proto-oncogene in human breast and ovarian cancer, Science 1989:244:707- 712.
22. Berns EMJJ, Foekens JA, VanPuttcn WIJ, VanStaveren IL, Portengen H, DcKoning WCH, Klijn JGM: Prognostic factors in human primary breast cancer: Comparison of c-myc and HER-2/neu amplification, J Steroid Biochcm Mol Biol 1992:43:13-19.
23. Hetzcl DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC: HER-2/neu expression: A major prognostic factor in endometrial cancer, Gynecol Oncol 1992:47:179-185.
24. Paterson MC, Dietrich KD, Danylauk J, Paterson AHG, Lees AW, Hanson J, Jenkins H, Krause BE, McBlain WA, Slamon DJ, Fournev RM: Correlation between c-crbB-2 amplification and risk of recurrent disease in node-negative breast cancer, Cancer Res 1991:51:556-567.
25. Noguchi M, Mizukami Y, Kinoshita K, Eara-shi M, Thomas M, Miyazaki I: Expression of c-erbB-2 and epidermal growth factor receptor in breast carcinoma: Prognostic value and correlation with clinicopathologica! and biological variables, Oncol Rep 1994;1:563-569.
26. Nicholson RI, McClelland RA, Finlay P, Elston CL, Gullick WJ, Dixon AR, Robertson JFR, Ellis IO, Blarney RW: Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity, EurJ Cancer 1993:29A: 1018-1023.
27. Sear T RW, Torloni H: Histological typing of breast tumors, International Histological Classification of Tumors, Geneva, World Health Organization, 1968, No 2.
28. crhB2by a novel monoclonal antibody (MAB-!45ww) in breast cancer membranes from estrogen and progesterone receptor assays, EurJ Cancer 1992;28:322-326.
29. Seharl A, Vicrbuchen B, Wiirz H: Immuno-histochemischer Nachweis von Ostrogen- und Progesteronrezeptoren mil Hilfe monoklonaler Antikorpcr in Mammakarzinomgeweben, Ver-gleich mit der biochemischen Rezeptoranalyse, Pathologe 1989;10:31-38.
30. Remmele W, Stegner HG: Immunohistoche-mischer Nachweis von Ostrogenrezcptoren (ER ICA) im Mammakarzinomgcwebe: Vor-schlag zur einheitlichen Formulierung des Un-tersuchungsbefundes, Dtsch Arztebl 1986:48: 3362-3364.
31. Beckmann MW, Tutschek B, Gohring UJ, Engels K, Picard FK, Scharl A, Niederacher D, Schnurch HG: Immunohistochemical identification of the epidermal growth factor receptor (EGF-R) in paraffin-embedded breast cancer specimens: Correlations and clinical ranking, Geburtshilfe Frauenheilkd 1995:55:258-265.
32. Beckmann MW, Tutschek B, Niederacher D, Risse BC, Ruppert C, Kriigcr KH, Schnurch HG, Bender HG: Biochemical and immunohistochemical detection of the epidermal growth factor receptor (EGF-R) in breast tumor specimens, Int J Oncol 1993;3:389-397.
33. ncu-oncoprotein indicates poor prognosis in small, node-negative breast cancer (T1N0) without adjuvant systemic treatment, Geburtshilfe Frauenheilkd 1993;53:625-629.
34. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer, N Engl J Med 1992;326: 1756-1761.
35. Stoschek CM, King LE: Role of epidermal growth factor in carcinogenesis, Cancer Res 1986:46:1030-1037.
36. Fitzpatrick SL, CaChance MP, Schultz GS: Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture, Cancer Res 1984;44:3442-3447.
37. Battaglia F, Scambia G, Rossi S, Panici PB, Bellantrone R, Polizzi G, Querzoli P, Ncgrini R, lacobelli S, Crucitti F, Mancuso S: Epidermal growth factor receptor in human breast cancer: Correlation with steroid hormone receptors and axillary lymph node involvement, Eur J Cancer Clin Oncol 1988:24:1685-1690.
38. Spitzer E, Grossc R, Kunde D, Schmidt HE: Growth of mammary epithelial cells in breast cancer biopsies correlates with EGF binding, Int J Cancer 1987:39:279-282.
39. Glenney JR, Chen WS, Lazar CS, Walton GM, Zokas LM, Rosenfcld MG, Gill GN: Ligand induced endocytosis of the EGF receptor is blocked by mutational inactivation and by microinjection of anti-phosphotyrosine antibodies, Cell 1988:52:675-684.
40. Klijn JGM, Berns PMJJ, Schmitz PIM, Foek-ens JA: The clinical significance of epidermal growth factors receptor (EGF-R) in human breast cancer: A review on 5232 patients, En-docrRcv 1992:13:3-17.
41. Berns PMJJ, Klijn JGM, Foekens JA: Oncogene amplification in human breast and ovarian cancer, Curr Pcrspect Mol Cell Oncol 1992: 1:81-94.
42. Harris AL, Nicholson S: Epidermal growth factor receptors in human breast cancer: in Lipp-man ME, Dickson RB (eds): Breast Cancer: Cellular and Molecular Biology, Boston, Kluw-er Academic Publ, 1988, vol 40, pp 93-118.
43. Spitzer E, Kocpke K, Kunde D, Schmidt HE: EGF binding is quantitatively related to growth in node-positive breast cancer, Breast Cancer Res Treat 1988:12:45-49.
44. Zeillinger R, Kury F, Spciscr R, Sliutz G, Czcr-wenka K, Kubista E: EGF-R and steroid receptors in breast cancer: A comparison with tumor grading, tumor size, lymph node involvement, and age, Clin Biochem 1993;26:221-227.
45. Borg A, Landon AK, Siggurdson H, Clark GM, Fcmo M, Fuqua SAW, Killander D, McGuire WL: HER-2/neu amplification predicts poor survival in node positive breast cancer, Cancer Res 1990:50:4332-4337.
46. Zeillinger R, Kury F, Czerwenka K, Kubista E, Sliutz G, Knogler W, Huber J, Zielinski C, Reiner G, Jakcsz R, Staffen A, Reiner A, Wrba F, Spona J: HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary' breast cancer, Oncogene 1989:4: 109-114.
47. Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lec-Chen GJ, Pounds GW, Vendely P, Owens M A, Pandian MR, McGuire WL: Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers, J Natl Cancer Inst 1992;84:1279-1282.
48. Sainsburv JRC, Malcolm AJ, Appleton DR, Famdon JR, Harris AL: Epidermal-growth-fac-tor receptor status as predictor of early recurrence of and death from breast cancer, Lancet 1987;i: 1398- 1402.
49. Rios M, Macias A, Perez R, Lage A, Skoog L: Receptors for epidermal grow th factor and estrogen as predictors of relapse in patients w ith mammary carcinoma, Anticancer Res 1988:8: 173-176.
50. Nicholson S, Halcrow P, Famdon JR, Sainsbu-ry JRC, Chambers P, Harris AL: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer, Lancet 1989;i: 182-184.
51. Pertschuk I.P, Kim DS, Nayer K, Feldman JG, Eisenberg KB, Carter AC, Rong ZT, Thelmo WL, Fleisher J, Greene GL: lmmunocyto-chemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies, Cancer 1990;6:1663-1670.
52. Nicholson S, Wright C, Sainsburv JR, Halcrow P, Kelly P, Angus B, Famdon JR, Harris AL: Epidermal growth factor receptor (EGFR) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure, J Steroid Biochem Mol Biol 1990:37:811-814.
53. Dc Borloli M, Dati C, Antoniotti S, Maggiora P, Sapei ML: Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells, J Steroid Biochem Mol Biol 1992:43:21-25.
54. Wada T, Qian X, Greene MI: Intermolecular association of the pi85 neu protein and EGF receptor modulates EGF receptor function, Cell 1990:61:1339-1347.
55. Harris AL, Nicholson S, Sainsbury RC, Fardon J, Wright C: Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions withneu, J Steroid Biochem 1989: 34:123-131.